This study suggests that NRF2/HO1 signaling may serve as a potential therapeutic target for BMSCs-Exos-based treatment for vitiligo, which might be beneficial to the clinical application of BMSCs-Exos for vitiligo. This evidence concerns the gene HMOX1 and vitiligo.